Huikang Wang

Huikang Wang

Auto-generated profile, based on publicly available information

Huikang Wang

Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, People’s Republic of China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2024 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
YZYang Zheng
Yang Zheng
LCLimei Cui
Limei Cui
HLHaoran Lu
Haoran Lu
ZLZhen Liu
Zhen Liu
ZZZhaoxue Zhai
Zhaoxue Zhai
YZYu Zhang
Yu Zhang
The intranasal (IN) route of drug delivery can effectively penetrate the blood-brain barrier and deliver drugs directly to the brain for the treatment of central nervous system (CNS) disorders via intra-neuronal or extra-neuronal pathways. This approach has several advantages, including avoidance of first-pass metabolism, high bioavailability, ease of administration, and improved patient compliance. In recent years, an increasing number of studies have been conducted using drugs encapsulated in solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), and delivering them to the brain via the IN pathway. SLNs are the first-generation solid lipid nanocarriers, known for their excellent biocompatibility, high drug-loading capacity, and remarkable stability. NLCs, regarded as the second-generation SLNs, not only retain the advantages of SLNs but also exhibit enhanced stability, effectively preventing drug leakage during storage. In this review, we examined in vivo studies conducted between 2019 and 2024 that used SLNs and NLCs to address CNS disorders via the IN route. By using statistical methods to evaluate pharmacokinetic parameters, we found that IN delivery of SLNs and NLCs markedly enhanced drug accumulation and targeting within the brain. Additionally, pharmacodynamic evaluations indicated that this delivery method substantially improved the therapeutic effectiveness of the drugs in alleviating symptoms in rat models of CNS diseases. In addition, methods for enhancing the efficacy of nose-to-brain delivery of SLNs and NLCs are discussed, as well as advances in clinical trials regarding SLNs and NLCs. Plain Language Summary: Traditional drug administration routes for the treatment of central nervous system diseases have many limitations due to the existence of the blood-brain barrier (BBB). The intranasal drug administration route crosses the BBB through intra-neuronal pathways as well as extra-neuronal pathways and delivers drugs directly to the brain. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) are a type of nanoparticles whose surface is covered by amphoteric surfactants and whose interior is filled with a lipid core. They have the advantages of good biocompatibility, strong drug loading capacity, and strong stability, and can be obtained through a variety of reliable preparation methods. Encapsulating therapeutic drugs into SLNs and NLCs for intranasal delivery can significantly increase drug delivery efficiency and enhance efficacy. In addition, there are various ways to further enhance drug delivery of SLNs and NLCs, such as using gel systems such as chitosan to encapsulate the nanoparticles, piggybacking cell-penetrating peptides onto the surface of the nanoparticles, and modifying the nanoparticles, surface charge of particles, etc.

1 October 2024 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
HWHuikang Wang
Huikang Wang
XXXinjun Xu
Xinjun Xu
HLHaoran Lu
Haoran Lu
YZYang Zheng
Yang Zheng
LSLiting Shao
Liting Shao
XSXicheng Song
Xicheng Song
Purpose: The pathogenesis of CRSwNP is complex and not yet fully explored, so we aimed to identify the pivotal hub genes and associated pathways of CRSwNP, to facilitate the detection of novel diagnostic or therapeutic targets. Methods: Utilizing two CRSwNP sequencing datasets from GEO, differential expression gene analysis, WGCNA, and three machine learning methods (LASSO, RF and SVM-RFE) were applied to screen for hub genes. A diagnostic model was then formulated utilizing hub genes, and the AUC was generated to evaluate the performance of the prognostic model and candidate genes. Hub genes were validated through the validation set and qPCR performed on normal mice and CRSwNP mouse model. Lastly, the ssGSEA algorithm was employed to assess the differences in immune infiltration levels. Results: A total of 239 DEGs were identified, with 170 upregulated and 69 downregulated in CRSwNP. Enrichment analysis revealed that these DEGs were primarily enriched in pathways related to nucleocytoplasmic transport and HIF-1 signaling pathway. Data yielded by WGCNA analysis contained 183 DEGs. The application of three machine learning algorithms identified 11 hub genes. Following concurrent validation analysis with the validation set and qPCR performed after establishing the mouse model confirmed the overexpression of BTBD10, ERAP1, GIPC1, and PEX6 in CRSwNP. The examination of immune cell infiltration suggested that the infiltration rate of type 2 T helper cell and memory B cell experienced a decline in the CRSwNP group. Conversely, the infiltration rates of Immature dendritic cell and Effector memory CD8 T cell were positive correlation. Conclusion: This study successfully identified and validated BTBD10, ERAP1, GIPC1, and PEX6 as potential novel diagnostic or therapeutic targets for CRSwNP, which offers a fresh perspective and a theoretical foundation for the diagnostic prediction and therapeutic approach to CRSwNP.

1 November 2026 in Journal of Asthma and Allergy
Verified
Journal Article
Open access
PDF file
HWHuikang Wang
Huikang Wang
XXXinjun Xu
Xinjun Xu
XSXicheng Song
Xicheng Song
YZYu Zhang
Yu Zhang
Biologics improve polyp burden, congestion, smell, quality of life, and rescue-treatment outcomes in severe chronic rhinosinusitis with nasal polyps (CRSwNP), yet individual responses remain heterogeneous and frequently discordant across clinical domains. This narrative Review examines why trial-level efficacy does not consistently become multidomain disease control. We propose that residual burden arises from five interacting sources: persistent or parallel inflammation, slowly reversible tissue remodeling, anatomy or impaired topical access, olfactory-compartment injury, and implementation failure. Epithelial alarmins, interleukin (IL)-4/IL-13 signaling, immunoglobulin E, eosinophil states, stromal programs, mixed or non-type 2 inflammation, and olfactory epithelial injury overlap rather than define mutually exclusive endotypes. Consequently, blood or tissue biomarkers can support a treatment hypothesis but do not yet predict the superior biologic for an individual patient. Randomized trials establish efficacy for several targets, whereas indirect comparisons, switching cohorts, interval-extension studies, and withdrawal data answer different and less certain questions. We therefore frame biologic treatment as a longitudinal experiment: define the patient-valued target, verify exposure and background care, measure domain-specific trajectories, explain residual disease, and match the next action to the unresolved mechanism. Emotional distress, adherence, affordability, and access are integrated within implementation failure because they determine whether pharmacological efficacy becomes durable real-world control. Future studies should prioritize treatment-interaction biomarkers, tissue-informed response phenotypes, direct comparisons, adaptive sequencing trials, and explicit definitions of on-treatment and treatment-free remission.